Skip to main content

Table 3 Summary of results of clinical trials with combinations of anti-PD-1/PD-L1 with targeted therapy

From: Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

Study name/code (NCT) Study phase Type of Cancer Treatment Patients evaluated for response Time to first tumor assessment (weeks) ORR by RECIST 1.1 criteria ORR by immune-related response criteria Patients treated beyond progression Response rate after initial PD First author and date of publication
20,150,932
(NCT02636725)
2 Sarcoma Pembrolizumab plus axitinib 32 12 8 (25.0%) 8 (25.0%) 4 (12.5%) Not reported Wilky 2019 [74]
A4061079
(NCT02133742)
1b RCC Pembrolizumab plus axitinib 52 12 38 (73.1%) Not reported 8 (15.4%) 1 (1.9%) Atkins 2018 [75]
BTCRC-GU14–003
(NCT02348008)
1b/2 RCC Pembrolizuamb plus bevacizumab 58 6 33 (56.9%) Not reported 7 (12.1%) Not reported Dudek 2020 [76]
CheckMate-012
(NCT01454102)
1 NSCLC Nivolumab Plus erlotinib 20 11 3 (15.0%) Not reported Not reported 1 (5.0%) Gettinger 2018 [77]
GP28328
(NCT01633970)
1b RCC Atezolizumab plus bevacizumab 10 6 4 (40.0%) Not reported 2 (20.0%) 1 (10.0%) Wallin 2016 [78]
KEYNOTE-146
(NCT02501096)
1b/2 Endometrial cancer Pembrolizumab plus lenvatinib 108 6 44 (40.7%) 47 (43.5%) Not reported Not reported Makker 2020 [79]
  1. Abbreviations: NCT ClinicalTrials.gov Identifier, NSCLC non-small-cell lung carcinoma, ORR overall response rate, PD progressive disease, RCC renal-cell carcinoma